Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform

Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform

Oncolytic viruses (OVs) have been shown to induce anti-cancer immunity and enhance cancer immunotherapies, such as immune checkpoint inhibitor therapies. OV therapies can be further improved by arming OVs with immunostimulatory molecules, including various cytokines or chemokines. Here, we have deve...

Full description

Bibliographic Details
Main Authors: Erkko Ylösmäki, Leena Ylösmäki, Manlio Fusciello, Beatriz Martins, Petra Ahokas, Hanne Cojoc, Arttu Uoti, Sara Feola, Anna Kreutzman, Tuuli Ranki, Julia Karbach, Tapani Viitala, Petri Priha, Elke Jäger, Sari Pesonen, Vincenzo Cerullo
Format: Article
Language:English
Published: Elsevier 2021-03-01
Series:Molecular Therapy: Oncolytics
Subjects:
oncolytic vaccine
CD40L
OX40L
T cell activation
PeptiCRAd
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770521000243

Internet

http://www.sciencedirect.com/science/article/pii/S2372770521000243

Similar Items